Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564796 · ClinicalTrials.gov registry record · Phase 2
Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial
A Phase 2 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02564796 is a Phase 2 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 4 participants.
The verdict
NCT02564796, a Phase 2 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Cyanotic congenital cardiac patients require higher hemoglobin concentrations (red blood cell levels) for optimal oxygen delivery to the body. Prophylactic erythropoietin (EPO) and iron can prevent and/or decrease the amount of blood transfusions needed in this population. We seek to investigate if EPO and iron make a clinically significant difference in the number of transfusions given to these patients and the morbidity associated with it.
Interventions
- DRUG Epoetin Alfa and Iron
- DRUG Iron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-11 |
| Est. Completion | 2020-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02564796
The ClinicalTrials.gov registry entry for NCT02564796 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epoetin Alfa and Iron is the first listed.
NCT02564796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02564796 about?
NCT02564796 is a clinical study titled "Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial". Cyanotic congenital cardiac patients require higher hemoglobin concentrations (red blood cell levels) for optimal oxygen delivery to the body. Prophylactic erythropoietin (EPO) and iron can prevent and/or decrease the amount of blood transfusions needed in this population. We seek to investigate if ...
What is the current status of trial NCT02564796?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2016-11. Estimated completion is 2020-06.
What interventions are being tested in trial NCT02564796?
The interventions under investigation include: Epoetin Alfa and Iron (DRUG), Iron (DRUG).
Who is sponsoring clinical trial NCT02564796?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.